| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
19 |
| Employees |
134 |
| Revenues (TTM) (Millions $) |
135 |
| Net Income (TTM) (Millions $) |
-107 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Novelion Therapeutics Inc. is a biopharmaceutical company that mainly focuses on the development and commercialization of drugs to treat patients with rare diseases. The company was formerly known as QLT Inc. It was founded in 1981 and is headquartered in Vancouver, Canada.
Novelion Therapeutics Inc. has a strong portfolio of products in various stages of development for treating rare diseases, including genetic disorders and complex lipid storage disorders. The companyes lead drug, Aegeriones JUXTAPIDe (lomitapide), is FDA approved and used to treat homozygous familial hypercholesterolemia (HoFH) - an ultra-rare genetic condition that affects fewer than one in a million people. JUXTAPIDe is designed to reduce cholesterol levels in patients by blocking the production of low-density lipoprotein (LDL) - a type of harmful cholesterol.
Apart from their lead drug, Novelion Therapeutics has other promising drugs in their pipeline, including myalepte (metreleptin) - a treatment for lipodystrophy, which is currently FDA approved, and zuretinol acetate (QLT091001) for the treatment of the rare inherited retinal disease, Leber congenital amaurosis. Additionally, the company is developing a pipeline of treatments for other genetic diseases with unmet medical needs, such as late-onset LAL deficiency (Wolman disease and cholesteryl ester storage disease [CESD]), and Alagille syndrome, among others.
Novelion Therapeutics works closely with regulatory bodies, including the FDA, to ensure smooth and efficient product development and approval processes. The company's management team comprises seasoned executives who bring a vast amount of experience in different pharmaceutical sectors, including business development, operations, clinical development, and regulatory affairs.
In conclusion, Novelion Therapeutics Inc. is a biopharmaceutical company that is focused on developing and commercializing innovative treatments for rare genetic disorders. Their strong product portfolio, experienced leadership team, and commitment to working with regulatory bodies make them a promising company in the field of rare diseases.
|
%